Fox Chase Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fox Chase Cancer Center sits in the top decile of US sponsors by registered trial count (#164 of 15,742 sponsors by registered trial count).
Fox Chase Cancer Center: 183 sponsored US clinical trials, 29 recruiting.
Fox Chase Cancer Center sponsors 183 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 104 completed. 5 of these trials are in Phase 3-4 (later-stage) and 107 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Urothelial Carcinoma, with 6 trials.
Top-decile sponsor footprint
Fox Chase Cancer Center ranks in the top decile of sponsors by registered trial count (#164 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
104 of 137 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
183 total, page 1 of 4
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
NCT07455032
Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
NCT07221942
Adaptive Radiation Boost for Rectal Cancer
NCT07221058
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
NCT07167446
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
NCT07219303
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
NCT06984562
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
NCT07043972
Testing Gene PilotLX With Latinx Cancer Patients
NCT06476938
Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.
NCT06914557
Understanding the Preferences and Views of Older Adults on the Use of Geriatric and Objective Functional Assessments for Cancer Treatment Planning.
NCT06652347
Communication About Sexual Health in Gynecologic Cancer
NCT06904339
Reducing Urban Cervical Cancer Disparities
NCT06416150
Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)
NCT06396533
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
NCT06782581
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
NCT06218628
Adaptive Radiation for Abdominopelvic Metastases
NCT05880667
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
NCT05800600
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
NCT05800574
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
NCT05800587
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
NCT05498792
African Cancer Genome: GMD
NCT05754658
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
NCT05454280
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
NCT05274048
Genomic Risk in Retroperitoneal Sarcoma
NCT06436846
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
NCT05263050
A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer
NCT04827810
PHL Treatment in Pancreatic Cancer
NCT05365893
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
NCT03786692
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
NCT03291028
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
NCT05923190
Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
NCT05360732
Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening
NCT04557423
Couples' QOL in Metastatic Breast Cancer
NCT05636943
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
NCT04506554
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
NCT03527108
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
NCT04452357
Organ Preservation in Early Rectal Cancer Patients
NCT03548961
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
NCT03179943
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
NCT03114527
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
NCT03125928
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT03172754
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
NCT02968732
Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
NCT04055753
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT02755272
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
NCT02710734
Perioperative Risk Study
NCT02456389
HPV Self-sampling for Underscreened Latinas
NCT06439706
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
NCT05420636
Feasibility, Acceptability and Fidelity of Integrating a Navigation Intervention Into Tobacco Treatment Program
NCT07072312
Women's Health Communication Study
NCT05359952
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 45 |
| Phase 2 | 62 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Fox Chase Cancer Center pipeline
29 recruiting of 183 indexed (16% open); 104 completed (57%).
Phase mix: 5 late (III/IV) vs 107 early (I/II) (early-phase heavy).
Top condition: Urothelial Carcinoma (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fox Chase Cancer Center: open-pipeline peers nationwide
Peers matched on 183 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
Fox Chase Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 183 trials (± recruiting share)
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
- ViiV Healthcare · 182 trials · 4% recruiting
- Boston University · 185 trials · 12% recruiting
- National Human Genome Research Institute (NHGRI) · 185 trials · 16% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- University of California, San Francisco · 16% recruiting · 1,713 trials
- Youngstown State University · 16% recruiting · 19 trials
- University of Southern California · 16% recruiting · 617 trials
Related
What to do with this Fox Chase Cancer Center page
183 registered trials is a research-attention snapshot, not an endorsement of Fox Chase Cancer Center or any single study.
- 29 of Fox Chase Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Urothelial Carcinoma is the condition Fox Chase Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Urothelial Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Fox Chase Cancer Center pipeline card: 183 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.